Table 2 Summary of HIV and HBV care algorithm for PRINCESSE participants
Group of patients | HIV and AgHBs negative | HIV-positive | HIV-negative AgHBs positive Fibrose ≥ F2 Elevated ALT and HBV DNA (eligible for HBV treatment) | HIV-negative AgHBs positive Fibrose < F2 Low HBV DNA et normal ALT (not eligible for HBV treatment) |
|---|---|---|---|---|
Hepatitis B vaccination | If not immunized (anti-HBs and anti-HBc both negatives) 3 regular doses at M0, M1, M6 | If not immunized (anti-HBs and anti-HBc both negatives) 4 double doses at M0, M1, M2, M6 | – | – |
Antiretroviral prescription | If creatinine clearance ≥ 60 mL/min and no contraindication TDF/FTC (1 pill/day) as oral PrEP | According to national guidelines As soon as possible, regardless of CD4 count Adapted regimen if HIV/HBV coinfection | If creatinine clearance ≥ 60 mL/min and no contraindication TDF/FTC (1 pill/day) as HBV treatment If creatinine clearance < 60 mL/min TDF with an adapted reduced dosage (1 pill every 1, 2, 3, or 7 days depending on the rate of creatinine clearance) | If creatinine clearance ≥ 60 mL/min and no contraindication TDF/FTC (1 pill/day) as oral PrEP |